Reduction of Calciprotein Particles in Adults Receiving Infliximab for Chronic Inflammatory Disease.

ABSTRACT: Patients with chronic inflammatory diseases (CID) experience accelerated loss of bone mineral density, which is often accompanied by increased vascular calcification. These disturbances can be attenuated by therapies for inflammation, such as the tumor necrosis factor inhibitor infliximab. Calciprotein particles (CPP) are circulating colloidal aggregates of calcium and phosphate together with the mineral-binding protein fetuin-A, which have emerged as potential mediators of vascular calcification. The precise origins of serum CPP are unclear, but bone turnover may be an important source. In this longitudinal observational study, we studied patients with CID undergoing treatment with infliximab to assess the temporal relationship between bone turnover and circulating CPP. Ten patients with

SUBMITTER: Tiong MK 

PROVIDER: S-EPMC8216135 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature